Uniunea Europeană - engleză - EMA (European Medicines Agency)

zentiva, k.s. - ivabradine hydrochloride - angina pectoris; heart failure - cardiac therapy - symptomatic treatment of chronic stable angina pectoris ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. ivabradine is indicated:in adults unable to tolerate or with a contra-indication to the use of beta-blockersorin combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. treatment of chronic heart failure ivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

Uniunea Europeană - engleză - EMA (European Medicines Agency)

les laboratoires servier - ivabradine hydrochloride - angina pectoris; heart failure - cardiac therapy - symptomatic treatment of chronic stable angina pectoris ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. ivabradine is indicated :in adults unable to tolerate or with a contraindication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.treatment of chronic heart failure ivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - nicorandil, quantity: 10 mg - tablet - excipient ingredients: pregelatinised maize starch; croscarmellose sodium; mannitol; stearic acid - for the treatment of chronic stable angina pectoris.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - nicorandil, quantity: 20 mg - tablet - excipient ingredients: stearic acid; pregelatinised maize starch; mannitol; croscarmellose sodium - for the treatment of chronic stable angina pectoris.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - nicorandil, quantity: 10 mg - tablet, uncoated - excipient ingredients: povidone; cetyl alcohol; croscarmellose sodium; sodium stearylfumarate; mannitol - nicorandil is indicated for the treatment of chronic stable angina pectoris.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - nicorandil, quantity: 20 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; mannitol; povidone; cetyl alcohol; sodium stearylfumarate - nicorandil is indicated for the treatment of chronic stable angina pectoris.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - isosorbide mononitrate, quantity: 60 mg - tablet, modified release - excipient ingredients: hypromellose; carnauba wax; stearic acid; lactose monohydrate; magnesium stearate; purified talc; titanium dioxide; iron oxide yellow; macrogol 4000; colloidal anhydrous silica - prophylactic treatment of angina pectoris. isodur mr 60mg sustained release tablets are not recommended for the management of acute attacks of angina pectoris.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pravastatin sodium, quantity: 40 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; lactose monohydrate; purified talc; magnesium stearate; aluminium magnesium silicate; povidone - 1. as an adjunct to diet for treatment of hyper cholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. 2. pravastatin is indicated in patients with previous myocardial infarction including those who have normal (4.0 to 5.5 mmol/l) serum cholesterol levels. 3. pravastatin is indicated in patients with unstable angina pectoris (see clinical trials). 4. cholstat is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trials).

Australia - engleză - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pravastatin sodium, quantity: 20 mg - tablet, uncoated - excipient ingredients: povidone; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; lactose monohydrate; aluminium magnesium silicate; purified talc - 1. as an adjunct to diet for treatment of hyper cholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. 2. pravastatin is indicated in patients with previous myocardial infarction including those who have normal (4.0 to 5.5 mmol/l) serum cholesterol levels. 3. pravastatin is indicated in patients with unstable angina pectoris (see clinical trials). 4. cholstat is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trials).

Australia - engleză - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pravastatin sodium, quantity: 10 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; croscarmellose sodium; povidone; purified talc; aluminium magnesium silicate; magnesium stearate; microcrystalline cellulose - 1. as an adjunct to diet for treatment of hyper cholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. 2. pravastatin is indicated in patients with previous myocardial infarction including those who have normal (4.0 to 5.5 mmol/l) serum cholesterol levels. 3. pravastatin is indicated in patients with unstable angina pectoris (see clinical trials). 4. cholstat is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trials).